PAM
MLTX icon

Panagora Asset Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Panagora Asset Management’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-7,212
Closed -$74K – 2114
2021
Q2 		$74K Sell
7,212
-41
-0.6% -$416 ﹤0.01% 1973
2021
Q1 		$74K Sell
7,253
-2,280
-24% -$25.1K ﹤0.01% 2112
2020
Q4 		$103K Buy
+9,533
New +$101K ﹤0.01% 1832

Other funds holding MLTX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Panagora Asset Management's MLTX Position: Q3 2021 in Review

Panagora Asset Management sold out of MoonLake Immunotherapeutics (MLTX) in Q3 2021, closing a stake of 7,212 shares — an estimated $74K sold.

Panagora Asset Management first reported a position in MLTX in Q4 2020 and held it in 3 quarters. The position peaked at $103K in Q4 2020. 43 funds tracked by Wall St. Rank hold MLTX as of Q3 2021.

  • Panagora Asset Management reported no remaining MoonLake Immunotherapeutics position as of Q3 2021 after selling out during the quarter.
  • Panagora Asset Management sold 7,212 MoonLake Immunotherapeutics shares in Q3 2021, an estimated $74K.
  • Panagora Asset Management first reported a position in MoonLake Immunotherapeutics in Q4 2020 and held it in 3 quarters.
  • Panagora Asset Management's MoonLake Immunotherapeutics position peaked at $103K in Q4 2020.
  • 43 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2021.

Based on Panagora Asset Management's 13F filing for Q3 2021, filed 10 Nov 2021.